• Citer

Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy

par De Cock, Emile ;Hutton, John;Canney, Peter;Body, Jean-Jacques ;Barrett-Lee, Peter;Neary, M.P.;Lewis, Gavin
Référence Supportive care in cancer, 13, 12, page (975-986)
Publication Publié, 2005-12

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Ibandronate is the first third-generation bisphosphonate to have both oral and intravenous (i.v.) efficacy. An incremental cost-effectiveness model compared oral ibandronate with i.v. zoledronic acid and i.v. generic pamidronate in female breast cancer patients with metastatic bone disease, undergoing i.v. chemotherapy.